Read more
19:09 · 2 December 2025

US Open: Wall Street Rebounds Supported by the Technology Sector

Wall Street is showing signs of stabilization today following yesterday’s sell-off. Futures on major indices are slightly higher, suggesting that the market is attempting to recover some of the losses.

The focus remains on the Federal Reserve’s decisions. Markets are speculating whether the Fed will shift its tone regarding future interest rate moves, which would have a significant impact on growth stock valuations, particularly in the technology sector. Technology companies and firms involved in artificial intelligence, which have been key drivers of gains in recent months, are now the most sensitive to market sentiment swings and changing expectations regarding monetary policy.

Additional pressure came from yesterday’s ISM Manufacturing PMI data, which showed that the U.S. industrial sector is again contracting. In November, the PMI stood at 48.2 points, down from 48.7 in October, marking the ninth consecutive month of weakening activity. Particularly concerning were declines in new orders, which fell to 47.4 points, and in the employment sub-index, which dropped to 44.0 points. At the same time, the prices index rose to 58.5 points, indicating growing cost pressures despite weakening demand.

This combination of data presents a challenge for the Fed. On one hand, weakening industrial activity and slowing demand suggest a cooling economy, which would normally support a more dovish monetary policy. On the other hand, persistent cost pressures could maintain inflation concerns and limit the scope for rapid rate cuts. As a result, the Fed may adopt a balanced and cautious approach, taking into account both economic risks and inflationary pressures.

Overall, the current market situation reflects a moderate rebound, uncertainty over future Fed actions, weak industrial data, and rising concerns about the health of technology companies.

Source: xStation5

 

US500 (H1 Interval)

S&P 500 futures are slightly higher today, marking a rebound from yesterday’s local correction. The market remains above key moving averages (EMA 25, 50, and 100), indicating technical dominance by bulls and the potential for continued gains. The RSI is in a neutral, slightly optimistic zone, suggesting that room for further upside remains. Markets remain moderately cautious, monitoring consolidation and upcoming macroeconomic data that could influence the market’s direction. Support around the moving averages remains stable, but upcoming market signals and global sentiment will be key.

Source: xStation5

Company News

  • Janux Therapeutics (JANX.US) shares fell sharply following the release of preliminary Phase 1 prostate cancer trial results. Despite generally positive safety and early efficacy data, the market reacted negatively, judging that the results do not provide a clear advantage over competing therapies and suggesting that the path to full commercialization may take longer.
     
  • Marvell Technology (MRVL.US) shares are up 2.5% intraday on news that the company is in advanced talks to acquire AI chip startup Celestial AI. The deal could exceed $5 billion and has the potential to strengthen Marvell’s position in the AI segment and accelerate the development of new technologies. At the same time, the market is cautious about integration challenges involving teams and technology. Investors also await Marvell’s third-quarter results, due after today’s session, which are expected to show EPS of $0.74 and revenues of $2.07 billion, representing year-on-year growth of 72% and 36%, respectively.
     
  • Credo Technology (CRDO.US) shares are rising intraday following results that exceeded market expectations and an optimistic outlook for upcoming quarters, with the stock gaining nearly 25%.
     
  • MongoDB (MDB.US) shares have surged over 20% after third-quarter results showed strong growth in Atlas platform revenues and increasing relevance in AI applications. Atlas revenues grew approximately 30%, and analysts forecast continued robust expansion in the coming years.
13 May 2026, 21:46

Daily Summary: Hot inflation and awaiting for news from Beijing

13 May 2026, 20:30

Trump–Xi: Who represents business and how are markets reacting?

13 May 2026, 18:56

US OPEN: Higher inflation to cap gains?

13 May 2026, 18:05

Birkenstock shares hit lowest level since IPO following earnings report 💥

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

The financial instruments we offer, especially CFDs, can be highly risky. Please consider if you understand the risks and can afford the loss of capital. XTB is regulated by the CMA

The financial instruments we offer, especially CFDs, can be highly risky. Please consider if you understand the risks and can afford the loss of capital. XTB is regulated by the CMA

The financial instruments we offer are risky. XTB is regulated by the CMA.